A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

Conditions: Thrombocythemia, Essential; Primary Myelofibrosis; Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis; Polycythemia Vera Interventions: Drug: Bomedemstat Sponsors: Merck Sharp& Dohme LLC Not yet recruiting

https://clinicaltrials.gov/study/NCT06351631

Source: ClinicalTrials.gov - April 8, 2024 Category: Research Source Type: clinical trials

More News: Merck | Research | Study